期刊
NEOPLASMA
卷 69, 期 1, 页码 165-173出版社
AEPRESS SRO
DOI: 10.4149/neo_2021_210924N1360
关键词
pancreatic ductal adenocarcinoma; cancer cell line; in vitro models; 3D culture
类别
资金
- Slovak Research and Development Agency [APVV-17-0037]
- Ministry of Education, Science, Research and Sport of the Slovak Republic (VEGA) [1/0279/18]
- European Regional Development Fund [ITMS: 313011AFG5]
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis. Surgery is only possible for a limited number of patients, while chemotherapy and radiotherapy can only extend survival. New in vitro and in vivo models are urgently needed to study this type of cancer.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive type of malignancy with one of the worst prognoses amongst any type of cancer. Surgery is applicable only to the limited number of patients with locally resectable tumors and currently represents the only curative treatment option. Treatment with chemotherapy and radiotherapy can only extend patient survival. Despite advances in conventional therapies, the five-year survival of PDAC remained largely unchanged. New in vitro and in vivo models are therefore urgently needed to investigate this type of cancer. Here, we present the establishment and characterization of a novel pancreatic cancer cell line, isolated from a patient with PDAC. Cell line abbreviated as PANDA (PANncreatic Ductal Adenocarcinoma) was established with an optimized 3D culture protocol published previously by our group. The new cancer cell line ???PANDA??? represents a novel in vitro approach for PDAC cancer research and new therapy testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据